Innate Pharma - ADR
IPHA - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$131.36M
Close$
$-0.16
111.4% downside
Current Fair Value
111.4% downsideOvervalued by 111.4% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $131.36 Million |
|---|---|
| Enterprise Value | $135.73 Million |
| Earnings per Share | $-0.53 |
| Beta | 0.88 |
| Outstanding Shares | 93,826,793 |
Return
| Return on Equity | 231.07% |
|---|---|
| Return on Assets | -269.55% |
| Return on Invested Capital | -5416.42% |
Valuation & Multiples
| P/E Ratio | -2.46 |
|---|---|
| PEG | 36.08 |
| Price to Sales | - |
| Price to Book Ratio | -1.4 |
| Enterprise Value to Revenue | 14.44 |
| Enterprise Value to EBIT | -1.34 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.08 |
| Debt to Equity | -0.27 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 5, 2026
EPS Estimate
$-0.29
Consensus analyst estimateRevenue Estimate
$6.35 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.02%▼ 0.19% |
|---|---|
| Total Invested | $34,136▼ 90.36% |
| Investors Holding | 2▼ 8.00% |
About Innate Pharma
244 employees
CEO: Mondher Mahjoubi
Innate Pharma S.A. is a biotechnology firm dedicated to the discovery, development, and commercialization of innovative antibody-based therapies, primarily for cancer indications, operating both in France and internationally. The company...